Celldex Therapeutics, Inc. Earnings Per Share Diluted

Quick Answer

Celldex Therapeutics, Inc. reported Earnings Per Share Diluted of $3.90 (loss) per share for the year ending 2025.

  • Celldex Therapeutics, Inc. showed a decrease of -59.2% in Earnings Per Share Diluted from 2024 to 2025.
  • This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), Celldex Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 11.1%.
  • Historical annual values: Fiscal year 2025: $3.90 (loss) per share | Fiscal year 2024: $2.45 (loss) per share | Fiscal year 2023: $2.92 (loss) per share | Fiscal year 2022: $2.40 (loss) per share | Fiscal year 2021: $1.64 (loss) per share | Fiscal year 2020: $2.02 (loss) per share | Fiscal year 2019: $3.51 (loss) per share.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: